| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | Doribax | |
| 3 | Generic Name | doripenem | |
| 4 | Indication | cUTI and cIAI | |
| 5 | Class | carbapenem | |
| 6 | Mechanism | active against a wide range of Gram-positive and Gram-negative bacterias | |
| 7 | Administration | IV | |
| 8 | Timeline | HAP complete response letter received 8/21/08. | |
| 9 | Clinical Trials | ||
| 10 | |||
| 11 | 83% clinical cure rate in patients with complicated intra-abdominal infections | ||
| 12 | n=486 (315 microbiologically evaluable), 83.3% doripenem cure rate and 83% for meropenem | ||
| 13 | 9.5% nausea, 7.4% diarrhea, 7% anemia, 6.6% vomiting |